Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Non-Current Deferred Tax Liability (2019 - 2020)

Silence Therapeutics (SLN) has disclosed Non-Current Deferred Tax Liability for 2 consecutive years, with $33011.3 as the latest value for Q4 2020.

  • Quarterly Non-Current Deferred Tax Liability rose 6.98% to $33011.3 in Q4 2020 from the year-ago period, while the trailing twelve-month figure was $33011.3 through Dec 2020, up 6.98% year-over-year, with the annual reading at $32103.7 for FY2020, 4.76% up from the prior year.
  • Non-Current Deferred Tax Liability hit $33011.3 in Q4 2020 for Silence Therapeutics, up from $30857.4 in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $33011.3 in Q4 2020 to a low of $30857.4 in Q4 2019.